PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005

被引：0
|
作者：
Riely, Gregory J. [1 ]
Kim, Dong-Wan [2 ]
Crino, Lucio [3 ]
Janne, Pasi A. [4 ]
Blackhall, Fiona H. [5 ]
Camidge, David R. [6 ]
Hirsh, Vera [7 ]
Mok, Tony S. K. [8 ]
Solomon, Ben [9 ]
Soria, Jean-Charles
Park, Keunchil [10 ]
Gadgeel, Shirish M. [11 ]
Martins, Renato G. [12 ]
Han, Ji-Youn
De Pas, Tommaso [13 ]
Bottomley, Andrew
Polli, Anna
Petersen, Jennifer A. [14 ]
Tassell, Vanessa R. [15 ]
Shaw, Alice T. [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Azienda Osped Perugia, Div Med, Perugia, Italy
[4] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Colorado Denver, Aurora, CO 80045 USA
[7] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada
[8] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[9] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[10] Sungkyunkwan Univ, Sch Med, Dept Med, Div Hem Onc, Seoul, South Korea
[11] Ayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Univ Washington, Seattle, WA 98195 USA
[13] European Inst Oncol, Thorac Oncol Unit, Milan, Italy
[14] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA
[15] Pfizer Oncol, Clin Res & Dev, New York, NY USA
[16] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Crizotinib; PF-02341066; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S411 / S412
页数：2
相关论文
共 50 条
  • [1] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [2] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [4] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [5] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] PROFILE 1005: PRELIMINARY PATIENT-REPORTED OUTCOMES (PROS) FROM AN ONGOING PHASE 2 STUDY OF CRIZOTINIB (PF-02341066) IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Blackhall, Fiona H.
    Petersen, Jennifer A.
    Wilner, Keith
    Hirsh, Vera
    Shaw, Alice T.
    Kim, Dong-Wan
    Solomon, Ben
    Janne, Pasi A.
    Reisman, Arlene L.
    Polli, Anna
    Mundayat, Rajiv
    Bottomley, Andrew
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S413 - S414
  • [7] Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors
    Li, C.
    Alvey, C.
    Bello, A.
    Wilner, K. D.
    Tan, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [9] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
12345